Streetbeat News

Regulatory

SINT

SINTX Technologies has been awarded a Phase II grant of $1,972,826 by the National Institutes of Health (NIH) to develop a 3D printed composite silicon nitride – polyetheretherketone (SN-PEEK) spinal implant. This is the fourth NIH grant awarded to SINTX. The company will collaborate with the University of Pennsylvania School of Veterinary Medicine over the next 24 months to execute this project. The NIH grant will support resourcing and acquisition of materials as well as testing and trials at SINTX and Penn Vet.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 1:02 pm

LXRX

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced that findings from two studies on the cost-effectiveness and budget impact of INPEFA, a drug recently approved by the FDA for heart failure treatment, will be presented at the Academy of Managed Care Pharmacy Nexus 2023 National Meeting. The company believes that the cost-effectiveness analysis and budget impact model for INPEFA will be crucial in driving decisions for formulary inclusion of this innovation.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 1:01 pm

EGPT

EIS

SPY

Egypt has discussed with the U.S. its plans to provide aid through its border with Gaza under a limited ceasefire, according to Egyptian security sources cited by Reuters.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 1:00 pm

MA

V

Mastercard's CFO, Sachin Mehra, has expressed concerns about the financial sustainability of India's Unified Payments Interface (UPI), despite its role in promoting digital transactions. The zero-cost transaction model of UPI has raised concerns about its long-term viability. This has been a concern for global card giants like Mastercard and Visa, who find it challenging to penetrate a market dominated by a cost-effective and government-supported payment system.

Portfolio Pulse from Anusuya Lahiri

October 11, 2023 | 12:49 pm

CNSP

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) has enrolled 229 of the expected 243 patients in its ongoing study evaluating Berubicin for the treatment of recurrent Glioblastoma Multiforme (GBM), an aggressive form of brain cancer. The company is on track to complete enrollment by year-end and expects to report interim analysis results later this quarter. The FDA has granted CNS Pharmaceuticals Fast Track Designation for Berubicin, which expedites the development and review process.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:48 pm

ONDS

Ondas Holdings Inc. (NASDAQ:ONDS) has appointed Timothy 'T3' Tenne as CEO of its wholly owned subsidiary, American Robotics Inc. Tenne, a former U.S. Air Force officer with extensive experience in global aviation and aerospace industries, will lead the scaling of the business to drive adoption of Ondas' autonomous drone platforms across the Americas. This follows the recent U.S. FAA Type Certification for the Optimus drone system. Tenne's leadership is expected to help manage operations in Israel and the Middle East during the current conflicts.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:44 pm

YTEN

Yield10 Bioscience, Inc. (NASDAQ:YTEN) has announced advancements in the development of herbicide tolerant Camelina, a crop used for production of low-carbon intensity feedstock oil for the biofuel market. The company is on track for a commercial launch of the first herbicide tolerant Camelina variety as early as 2025. Yield10 is also developing an herbicide package for Camelina, incorporating tolerance to broadleaf herbicide and soil residual Group 2 herbicides. The company has filed a request for Regulatory Status Review with USDA-APHIS Biotechnology Regulatory Services for its herbicide tolerant Camelina.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:41 pm

RLMD

Relmada Therapeutics, Inc. (NASDAQ:RLMD) announced new preclinical data on its novel psilocybin, showing significant reductions in liver fat content, plasma glucose levels, and body weight gain in a mice model. The company plans to initiate a single-ascending dose Phase 1 trial in patients in early 2024. The data will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2023.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:41 pm

GOOG

GOOGL

Google, a subsidiary of Alphabet Inc, and Discord Inc have been hosting a chat for users of Bard, Google's AI-powered chatbot. There are concerns about the reliability of large language models (LLMs) like Bard, and the need for independent verification of their outputs. Users have raised concerns about Bard generating inaccurate information and potentially hazardous advice. Google has introduced a search button on Bard to allow users to validate the AI-generated responses. The success of Bard is crucial for Google as generative AI technologies threaten Google's dominance in the search market.

Portfolio Pulse from Anusuya Lahiri

October 11, 2023 | 12:40 pm

EIS

SPY

USO

VGK

Russian President Putin has stated that the conflict in Israel could affect logistics but not oil output. He also mentioned that the U.S. is increasing tensions in the region by deploying its navy.

Portfolio Pulse from Charles Gross

October 11, 2023 | 12:39 pm